This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 March - 6 April 2024 and includes updates on SARS-CoV-2, cholera, avian influenza A(H5N1), swine influenza A(H1N2) and Middle East respiratory syndrome coronavirus (MERS-CoV).
Since the beginning of 2024, and as of 3 April, no MERS-CoV cases have been reported by WHO or national health authorities. The last reported case was in Saudi Arabia, with date of onset on 26 October 2023.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.